CME: Pharmacotherapy for Hepatocellular Carcinoma (HCC): Therapeutic Updates, Best Practices, and Emerging Therapies
ACCREDITATION EXPIRED: February 19, 2021
AN ACCREDITED UP-TO-DATE VERSION OF THIS TOPIC CAN BE FOUND AT:Activity Description / Statement of Need:
In this online, self-learning activity:
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths and one of the more common types of cancer affecting the population worldwide. It is an aggressive form of liver cancer occurring with increasing incidence and in 78% of cases worldwide is caused by hepatitis B and hepatitis C virus infections. HCC is often fatal as it is primarily diagnosed in the advanced disease state and carries a grim prognosis: 5-year survival rates are typically no more than ten percent. Though the etiology itself can be complex, improvements in screening and treatments may help to reduce the burden of HCC in the population worldwide.
It has also been determined that by doing surveillance in high risk individuals, HCC can be caught much earlier and therefore have a more positive prognosis potentially leading to increased rates of survival. Screening guidelines for HCC released by the American Association for the Study of Liver Diseases (AASLD) include recommendations by ethnicity, exposures, disease states, and family history. Updated information is also available regarding serologic markers used in the screening process. As the incidence of HCC increases, there will be a greater need to increase surveillance and screening of it in at risk populations. By diagnosing HCC earlier, more curative treatment options are available and the prognosis improves.
Target Audience:
The following healthcare professionals: medical oncologists, hepatologists, interventional radiologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with HCC, and. patients and/or their caregivers may also derive benefit from participating in the learning activity.
Commercial Support Disclosure: This program is supported by educational grants from Eisai.
Release Date: February 19, 2019 -- Expiration Date: February 19, 2021
Faculty: Laleh Melstrom, MD
Agenda
|
Faculty introduction, disclosures |
|
|
Introduction content: cursory refresher and review
|
|
|
Treatment of HCC
|
|
|
Summary, conclusions, and best practice recap |
|
Learning Objectives
By the end of the session the participant will be able to:
- Apply existing guideline recommendations in the diagnosis of HCC
- Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
- Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
- Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Leah Melstrom, MD has no relevent financial discloses.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial discloses.
Commercial Support Disclosure: This program is supported by educational grants from Eisai
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Addressing skeletal-related events in prostate cancer
Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment
Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments